BMJ  2005;330:117 (15 January), doi:10.1136/bmj.38316.729907.8F (published 23 December 2004)

Paper

Bronchodilator treatment and deaths from asthma: case-control study

H Ross Anderson, professor of epidemiology and public health1, Jon G Ayres, professor of environmental and occupational medicine2, Patricia M Sturdy, senior research fellow1, J Martin Bland, professor of medical statistics1, Barbara K Butland, lecturer in medical statistics1, Clare Peckitt, statistician1, Jennifer C Taylor, research manager1, Christina R Victor, professor of social gerontology1, for the Mortality and Severe Morbidity Group of the National Asthma Task Force

1 Department of Community Health Sciences, St George's Hospital Medical School, London SW17 0RE, 2 Department of Environmental and Occupational Medicine, Liberty Safe Work Research Centre, University of Aberdeen, Aberdeen AB25 2ZP

Correspondence to: H R Anderson r.anderson{at}sghms.ac.uk

Objective To investigate the association between bronchodilator treatment and death from asthma.

Design Case-control study.

Setting 33 health authorities or health boards in Great Britain.

Participants 532 patients under age 65 who died from asthma and 532 controls with a hospital admission for asthma matched for period, age, and area.

Main outcome measures Odds ratios for deaths from asthma associated with prescription of bronchodilators and other treatment, with sensitivity analyses adjusting for age at onset, previous hospital admissions, associated chronic obstructive lung disease, and number of other drug categories.

Results After full adjustment, there were no significant associations with drugs prescribed in the 4-12 months before the index date. For prescriptions in the 1-5 years before, mortality was positively associated with inhaled short acting {beta}2 agonists (odds ratio 2.05, 95% confidence interval 1.26 to 3.33) and inversely associated with antibiotics (0.59, 0.39 to 0.89). The former association seemed to be confined to those aged 45-64, and the association with antibiotics was more pronounced in those under 45. Significant age interactions across all periods suggested inverse associations with oral steroids confined to the under 45 age group. An inverse association with long acting {beta}2 agonists and a positive association with methylxanthines in the 1-5 year period were non-significant.

Conclusion There was no evidence of adverse effects on mortality with medium to long term use of inhaled long acting {beta}2 agonist drugs. The association with short acting {beta}2 agonists has several explanations, only one of which may be a direct adverse effect.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Shedding light on role of {beta}2 agonists in deaths from asthma
BMJ 2005 330: 0. [Full Text] [PDF]

This article has been cited by other articles:

  • Wijesinghe, M., Weatherall, M., Perrin, K., Harwood, M., Beasley, R. (2009). Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J 34: 803-811 [Abstract] [Full text]  
  • Johnston, S. L, Edwards, M. R (2009). Mechanisms of adverse effects of {beta}-agonists in asthma. Thorax 64: 739-741 [Full text]  
  • Beasley, R., Martinez, F. D., Hackshaw, A., Rabe, K. F., Sterk, P. J., Djukanovic, R. (2009). Safety of long-acting {beta}-agonists: urgent need to clear the air remains. Eur Respir J 33: 3-5 [Full text]  
  • LANG, D. M. (2008). New asthma guidelines emphasize control, regular monitoring. Cleveland Clinic Journal of Medicine 75: 641-653 [Abstract] [Full text]  
  • Wijesinghe, M, Perrin, K, Harwood, M, Weatherall, M, Beasley, R (2008). The risk of asthma mortality with inhaled long acting {beta}-agonists. Postgrad. Med. J. 84: 467-472 [Abstract] [Full text]  
  • Bateman, E., Nelson, H., Bousquet, J., Kral, K., Sutton, L., Ortega, H., Yancey, S. (2008). Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events. ANN INTERN MED 149: 33-42 [Abstract] [Full text]  
  • Greening, A. P., Stempel, D., Bateman, E. D., Virchow, J. C. (2008). Managing asthma patients: which outcomes matter?. ERR 17: 53-61 [Abstract] [Full text]  
  • Ross Anderson, H, Gupta, R., Strachan, D. P, Limb, E. S (2007). 50 years of asthma: UK trends from 1955 to 2004. Thorax 62: 85-90 [Abstract] [Full text]  
  • Glassroth, J. (2006). The Role of Long-Acting {beta}-Agonists in the Management of Asthma: Analysis, Meta-Analysis, and More Analysis. ANN INTERN MED 144: 936-937 [Full text]  
  • Nelson, H. S., Weiss, S. T., Bleecker, E. R., Yancey, S. W., Dorinsky, P. M., the SMART Study Group, (2006). The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest 129: 15-26 [Abstract] [Full text]  
  • Martinez, F. D. (2005). Safety of Long-Acting Beta-Agonists -- An Urgent Need to Clear the Air. NEJM 353: 2637-2639 [Full text]  
  • Sturdy, P M, Butland, B K, Anderson, H R, Ayres, J G, Bland, J M, Harrison, B D W, Peckitt, C, Victor, C R, on behalf of the National Asthma Campaign Mortalit, (2005). Deaths certified as asthma and use of medical services: a national case-control study. Thorax 60: 909-915 [Abstract] [Full text]  
  • Currie, G. P., Lee, D. K. C., Srivastava, P. (2005). Long-Acting Bronchodilator or Leukotriene Modifier as Add-on Therapy to Inhaled Corticosteroids in Persistent Asthma?. Chest 128: 2954-2962 [Abstract] [Full text]  
  • Price, G (2005). Asthma deaths and bronchodilator therapy. Thorax 60: 413-413 [Full text]  
  • Kelly, H W. (2005). What Is New with the {beta}2-Agonists: Issues in the Management of Asthma. The Annals of Pharmacotherapy 39: 931-938 [Abstract] [Full text]  
  • Currie, G. P, Devereux, G. S, Lee, D. K C, Ayres, J. G (2005). Recent developments in asthma management. BMJ 330: 585-589 [Full text]  
  • (2005). Relation Between {beta}-Agonists and Asthma Mortality Varies. JWatch General 2005: 6-6 [Full text]  

Rapid Responses:

Read all Rapid Responses

Do beta-agonists make asthma worse?
Gareth I Lloyd
bmj.com, 14 Jan 2005 [Full text]
Another clue to an unanswered question
Christos S Zipitis, et al.
bmj.com, 22 Jan 2005 [Full text]
Mortality Rates In Those Using Beta-Agonist and Beta-Blocking Agents
Alistair C Lindsay, et al.
bmj.com, 23 Jan 2005 [Full text]
Re: Do beta-agonists make asthma worse?
George Strube
bmj.com, 24 Jan 2005 [Full text]
Re: Do beta-agonists make asthma worse?
Gareth Lloyd
bmj.com, 25 Jan 2005 [Full text]
Clear and Present Danger: The Beta2-Agonist Saga
Daniel K C Lee
bmj.com, 27 Jan 2005 [Full text]
Benefit of inhaled steroids appear understated
David Lewis
bmj.com, 28 Jan 2005 [Full text]
Non-compliance in Dual Overusers May Lead to Death from Asthma
Mihai S. Jalba, M.D., Ph.D., et al.
bmj.com, 8 Feb 2005 [Full text]
Hypokalemia-induced arrhythmia – the assassin in beta 2 agonist treated patients?
Henning Bundgaard, et al.
bmj.com, 27 Mar 2005 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ